CLDX
What one share of Celldex Therapeutics holds
In Vitro and In Vivo Diagnostic Substances
Celldex Therapeutics, Inc., which we refer to as “Celldex,” “we,” “us,” “our” or the “Company,” is a biopharmaceutical company dedicated to exploring the science of mast cell biology and developing therapeutic antibodies which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases.
Celldex Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$4.33 |
| Capex (buildings and equipment) | $0.09 |
| Free cash flow | −$3.49 |
| Cash and investments | $9.14 |
| Book value | $9.10 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | $11.49 | −$27.64 | $0.40 | −$23.00 | — | $55.82 |
| 2010 | $22.03 | −$1.19 | $0.99 | −$15.28 | — | $35.21 |
| 2011 | $3.52 | −$17.01 | $0.19 | −$13.73 | — | $23.32 |
| 2012 | $2.91 | −$15.37 | $0.08 | −$13.02 | — | $22.32 |
| 2013 | $0.77 | −$15.33 | $0.79 | −$13.52 | — | $53.75 |
| 2014 | $0.60 | −$19.81 | $0.32 | −$17.36 | — | $35.44 |
| 2015 | $0.85 | −$19.66 | $0.75 | −$16.04 | — | $44.10 |
| 2016 | $1.00 | −$18.99 | $0.41 | −$17.11 | — | $33.04 |
| 2017 | $1.49 | −$10.86 | $0.21 | −$11.87 | — | $25.60 |
| 2018 | $0.91 | −$14.48 | $0.08 | −$7.28 | — | $10.38 |
| 2019 | $0.25 | −$3.51 | $0.05 | −$3.25 | — | $5.54 |
| 2020 | $0.25 | −$2.02 | $0.05 | −$1.42 | — | $5.29 |
| 2021 | $0.11 | −$1.64 | $0.03 | −$1.45 | — | $8.98 |
| 2022 | $0.05 | −$2.40 | $0.04 | −$2.25 | — | $6.91 |
| 2023 | $0.14 | −$2.92 | $0.04 | −$2.25 | — | $7.68 |
| 2024 | $0.11 | −$2.45 | $0.03 | −$2.48 | — | $11.25 |
| 2025 | $0.02 | −$3.90 | $0.04 | −$3.22 | — | $7.92 |